Report cover image

Global Quetiapine Fumarate Sustained Release Tablets Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 196 Pages
SKU # APRC20283813

Description

Summary

According to APO Research, The global Quetiapine Fumarate Sustained Release Tablets market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Quetiapine Fumarate Sustained Release Tablets is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Quetiapine Fumarate Sustained Release Tablets is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Quetiapine Fumarate Sustained Release Tablets is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Quetiapine Fumarate Sustained Release Tablets is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Quetiapine Fumarate Sustained Release Tablets include Dr. Reddy's Laboratories, Lupin Limited, Luye Pharma Limited, PHARMATHEN INVESTMENTS GROUP LIMITED, Seroquel, Torrent Pharmaceuticals, Mylan N.V., Sandoz and Sun Pharmaceutical Industries, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Quetiapine Fumarate Sustained Release Tablets, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Quetiapine Fumarate Sustained Release Tablets, also provides the revenue of main regions and countries. Of the upcoming market potential for Quetiapine Fumarate Sustained Release Tablets, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Quetiapine Fumarate Sustained Release Tablets revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Quetiapine Fumarate Sustained Release Tablets market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Quetiapine Fumarate Sustained Release Tablets revenue, projected growth trends, production technology, application and end-user industry.

Quetiapine Fumarate Sustained Release Tablets Segment by Company

Dr. Reddy's Laboratories
Lupin Limited
Luye Pharma Limited
PHARMATHEN INVESTMENTS GROUP LIMITED
Seroquel
Torrent Pharmaceuticals
Mylan N.V.
Sandoz
Sun Pharmaceutical Industries
Teva Pharmaceutical Industries
Quetiapine Fumarate Sustained Release Tablets Segment by Type

50mg
200mg
300mg
400mg
Quetiapine Fumarate Sustained Release Tablets Segment by Application

Hospital
Clinic
Others
Quetiapine Fumarate Sustained Release Tablets Segment by Region

North America
United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Quetiapine Fumarate Sustained Release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Quetiapine Fumarate Sustained Release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Quetiapine Fumarate Sustained Release Tablets.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Quetiapine Fumarate Sustained Release Tablets in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Quetiapine Fumarate Sustained Release Tablets company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Quetiapine Fumarate Sustained Release Tablets revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

196 Pages
1 Market Overview
1.1 Product Definition
1.2 Quetiapine Fumarate Sustained Release Tablets Market by Type
1.2.1 Global Quetiapine Fumarate Sustained Release Tablets Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 50mg
1.2.3 200mg
1.2.4 300mg
1.2.5 400mg
1.3 Quetiapine Fumarate Sustained Release Tablets Market by Application
1.3.1 Global Quetiapine Fumarate Sustained Release Tablets Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Quetiapine Fumarate Sustained Release Tablets Market Dynamics
2.1 Quetiapine Fumarate Sustained Release Tablets Industry Trends
2.2 Quetiapine Fumarate Sustained Release Tablets Industry Drivers
2.3 Quetiapine Fumarate Sustained Release Tablets Industry Opportunities and Challenges
2.4 Quetiapine Fumarate Sustained Release Tablets Industry Restraints
3 Global Growth Perspective
3.1 Global Quetiapine Fumarate Sustained Release Tablets Market Perspective (2020-2031)
3.2 Global Quetiapine Fumarate Sustained Release Tablets Growth Trends by Region
3.2.1 Global Quetiapine Fumarate Sustained Release Tablets Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Quetiapine Fumarate Sustained Release Tablets Market Size by Region (2020-2025)
3.2.3 Global Quetiapine Fumarate Sustained Release Tablets Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Quetiapine Fumarate Sustained Release Tablets Revenue by Players
4.1.1 Global Quetiapine Fumarate Sustained Release Tablets Revenue by Players (2020-2025)
4.1.2 Global Quetiapine Fumarate Sustained Release Tablets Revenue Market Share by Players (2020-2025)
4.1.3 Global Quetiapine Fumarate Sustained Release Tablets Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Quetiapine Fumarate Sustained Release Tablets Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Quetiapine Fumarate Sustained Release Tablets Key Players Headquarters & Area Served
4.4 Global Quetiapine Fumarate Sustained Release Tablets Players, Product Type & Application
4.5 Global Quetiapine Fumarate Sustained Release Tablets Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Quetiapine Fumarate Sustained Release Tablets Market CR5 and HHI
4.6.3 2024 Quetiapine Fumarate Sustained Release Tablets Tier 1, Tier 2, and Tier 3
5 Quetiapine Fumarate Sustained Release Tablets Market Size by Type
5.1 Global Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2020-2031)
5.3 Global Quetiapine Fumarate Sustained Release Tablets Revenue Market Share by Type (2020-2031)
6 Quetiapine Fumarate Sustained Release Tablets Market Size by Application
6.1 Global Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2020-2031)
6.3 Global Quetiapine Fumarate Sustained Release Tablets Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Dr. Reddy's Laboratories
7.1.1 Dr. Reddy's Laboratories Comapny Information
7.1.2 Dr. Reddy's Laboratories Business Overview
7.1.3 Dr. Reddy's Laboratories Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2020-2025)
7.1.4 Dr. Reddy's Laboratories Quetiapine Fumarate Sustained Release Tablets Product Portfolio
7.1.5 Dr. Reddy's Laboratories Recent Developments
7.2 Lupin Limited
7.2.1 Lupin Limited Comapny Information
7.2.2 Lupin Limited Business Overview
7.2.3 Lupin Limited Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2020-2025)
7.2.4 Lupin Limited Quetiapine Fumarate Sustained Release Tablets Product Portfolio
7.2.5 Lupin Limited Recent Developments
7.3 Luye Pharma Limited
7.3.1 Luye Pharma Limited Comapny Information
7.3.2 Luye Pharma Limited Business Overview
7.3.3 Luye Pharma Limited Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2020-2025)
7.3.4 Luye Pharma Limited Quetiapine Fumarate Sustained Release Tablets Product Portfolio
7.3.5 Luye Pharma Limited Recent Developments
7.4 PHARMATHEN INVESTMENTS GROUP LIMITED
7.4.1 PHARMATHEN INVESTMENTS GROUP LIMITED Comapny Information
7.4.2 PHARMATHEN INVESTMENTS GROUP LIMITED Business Overview
7.4.3 PHARMATHEN INVESTMENTS GROUP LIMITED Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2020-2025)
7.4.4 PHARMATHEN INVESTMENTS GROUP LIMITED Quetiapine Fumarate Sustained Release Tablets Product Portfolio
7.4.5 PHARMATHEN INVESTMENTS GROUP LIMITED Recent Developments
7.5 Seroquel
7.5.1 Seroquel Comapny Information
7.5.2 Seroquel Business Overview
7.5.3 Seroquel Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2020-2025)
7.5.4 Seroquel Quetiapine Fumarate Sustained Release Tablets Product Portfolio
7.5.5 Seroquel Recent Developments
7.6 Torrent Pharmaceuticals
7.6.1 Torrent Pharmaceuticals Comapny Information
7.6.2 Torrent Pharmaceuticals Business Overview
7.6.3 Torrent Pharmaceuticals Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2020-2025)
7.6.4 Torrent Pharmaceuticals Quetiapine Fumarate Sustained Release Tablets Product Portfolio
7.6.5 Torrent Pharmaceuticals Recent Developments
7.7 Mylan N.V.
7.7.1 Mylan N.V. Comapny Information
7.7.2 Mylan N.V. Business Overview
7.7.3 Mylan N.V. Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2020-2025)
7.7.4 Mylan N.V. Quetiapine Fumarate Sustained Release Tablets Product Portfolio
7.7.5 Mylan N.V. Recent Developments
7.8 Sandoz
7.8.1 Sandoz Comapny Information
7.8.2 Sandoz Business Overview
7.8.3 Sandoz Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2020-2025)
7.8.4 Sandoz Quetiapine Fumarate Sustained Release Tablets Product Portfolio
7.8.5 Sandoz Recent Developments
7.9 Sun Pharmaceutical Industries
7.9.1 Sun Pharmaceutical Industries Comapny Information
7.9.2 Sun Pharmaceutical Industries Business Overview
7.9.3 Sun Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2020-2025)
7.9.4 Sun Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Product Portfolio
7.9.5 Sun Pharmaceutical Industries Recent Developments
7.10 Teva Pharmaceutical Industries
7.10.1 Teva Pharmaceutical Industries Comapny Information
7.10.2 Teva Pharmaceutical Industries Business Overview
7.10.3 Teva Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2020-2025)
7.10.4 Teva Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Product Portfolio
7.10.5 Teva Pharmaceutical Industries Recent Developments
8 North America
8.1 North America Quetiapine Fumarate Sustained Release Tablets Revenue (2020-2031)
8.2 North America Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2020-2031)
8.2.1 North America Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2020-2025)
8.2.2 North America Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2026-2031)
8.3 North America Quetiapine Fumarate Sustained Release Tablets Revenue Share by Type (2020-2031)
8.4 North America Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2020-2031)
8.4.1 North America Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2020-2025)
8.4.2 North America Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2026-2031)
8.5 North America Quetiapine Fumarate Sustained Release Tablets Revenue Share by Application (2020-2031)
8.6 North America Quetiapine Fumarate Sustained Release Tablets Revenue by Country
8.6.1 North America Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2020-2025)
8.6.3 North America Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
8.6.6 Mexico
9 Europe
9.1 Europe Quetiapine Fumarate Sustained Release Tablets Revenue (2020-2031)
9.2 Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2020-2031)
9.2.1 Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2020-2025)
9.2.2 Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2026-2031)
9.3 Europe Quetiapine Fumarate Sustained Release Tablets Revenue Share by Type (2020-2031)
9.4 Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2020-2031)
9.4.1 Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2020-2025)
9.4.2 Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2026-2031)
9.5 Europe Quetiapine Fumarate Sustained Release Tablets Revenue Share by Application (2020-2031)
9.6 Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Country
9.6.1 Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2020-2025)
9.6.3 Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
9.6.9 Spain
9.6.10 Netherlands
9.6.11 Switzerland
9.6.12 Sweden
9.6.13 Poland
10 China
10.1 China Quetiapine Fumarate Sustained Release Tablets Revenue (2020-2031)
10.2 China Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2020-2031)
10.2.1 China Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2020-2025)
10.2.2 China Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2026-2031)
10.3 China Quetiapine Fumarate Sustained Release Tablets Revenue Share by Type (2020-2031)
10.4 China Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2020-2031)
10.4.1 China Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2020-2025)
10.4.2 China Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2026-2031)
10.5 China Quetiapine Fumarate Sustained Release Tablets Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Quetiapine Fumarate Sustained Release Tablets Revenue (2020-2031)
11.2 Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2020-2031)
11.2.1 Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2020-2025)
11.2.2 Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2026-2031)
11.3 Asia Quetiapine Fumarate Sustained Release Tablets Revenue Share by Type (2020-2031)
11.4 Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2020-2031)
11.4.1 Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2020-2025)
11.4.2 Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2026-2031)
11.5 Asia Quetiapine Fumarate Sustained Release Tablets Revenue Share by Application (2020-2031)
11.6 Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Country
11.6.1 Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2020-2025)
11.6.3 Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue (2020-2031)
12.2 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2020-2031)
12.2.1 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2020-2025)
12.2.2 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2026-2031)
12.3 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue Share by Type (2020-2031)
12.4 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2020-2031)
12.4.1 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2020-2025)
12.4.2 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2026-2031)
12.5 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue Share by Application (2020-2031)
12.6 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Country
12.6.1 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2020-2025)
12.6.3 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.